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Background
Rivastigmin tartarat is a dual, reversible cholinesterase
inhibitor (acetil and butril). Its chemical composition is
(S)-N-ethyl-N-methyl-3-1-dimethylamin - ethyl-phenyl
carbamat hydrogen-(2R,3R)-tartrat. FDA has approved
its use in treatment of Alzheimer dementia and demen-
tia in combination with Parkison disease. In addition to
this, results based on small clinical studies and case
reports showed positive efects of rivastigmin tartarat in
therapy applied in numerous pyschiatric disorders.
Materials and methods
In this study 11 patients have been observed. According
to ICD-10 they all satisfied criteria for diagnosis of resi-
dual schizophrenia and had a score of below 24 at
MMSE and high scores at NPI 12 and BPRS. During the
period of 60 days, apart from antipsychotics and anxio-
litics or psychostabilisers, patients also received rivasti-
gmin tartarat in their therapy.
Results
The study showed that rivastigmine therapy produced
significant improvements when it comes to cognition
and reduction of disorders in the sphere of afective-
behavioristic functioning of patients with residual schi-
zophrenia. However, this interpretation cannot be con-
firmed to be completely valid due to the size of treated
group, the absence of the control group, and the length
of the observing period.
Conclusions
Dual cholinesterase inhibitors (Ach and BuCh) may pro-
duce improvement in cognition and behavioural perfor-
mances, as well as the general quality of life with
patients diagnosede with residual schizophrenia. Future
studies applied on this kind of patients should precisely
explain the basic farmachological mechanisams of rivas-
tigmin tartarat, and approve/disapprove the results of
clinical studies and case reports that have been pre-
formed so far.
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